Axis III disorders in treatment-resistant major depressive disorder

George I. Papakostas, Timothy Petersen, Dan V. Iosifescu, Pamela A. Roffi, Jonathan E. Alpert, Jerrold F. Rosenbaum, Maurizio Fava, Andrew A. Nierenberg

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

A number of naturalistic studies have found that medical co-morbidity conveys a worse long-term prognosis in the treatment of major depressive disorder (MDD). The purpose of this study was to test whether the presence of co-morbid medical conditions can predict clinical response in patients with treatment-resistant MDD (TRD) treated with open-label nortriptyline (NT). Ninety-two patients with TRD entered a 6-week open trial of NT. The presence of co-morbid medical disorders was assessed during the screen visit. The degree of medical co-morbidity during the screen visit was then quantified with the use of the Cumulative Illness Rating Scale - Geriatric Version (CIRS(G)). We tested whether CIRS(G) scores predicted clinical response or depression severity at endpoint. CIRS scores at baseline did not significantly predict treatment response. The results of this study fail to confirm the relationship between co-morbid medical conditions and poor outcome in the treatment of MDD for patients with TRD. Patients with TRD and co-morbid medical conditions can be expected to respond to antidepressants as well as their counterparts without concurrent axis III co-morbidity. The CIRS(G) scores for this TRD sample were lower than those reported for geriatric depression, or for depressed patients with severe medical illness, common in medical and surgical wards and in most specialty clinics of large academic centers. Thus, the present results cannot be generalized to such populations.

Original languageEnglish (US)
Pages (from-to)183-188
Number of pages6
JournalPsychiatry Research
Volume118
Issue number2
DOIs
StatePublished - May 30 2003
Externally publishedYes

Fingerprint

Treatment-Resistant Depressive Disorder
Major Depressive Disorder
Geriatrics
Nortriptyline
Morbidity
Therapeutics
Depression
Antidepressive Agents
Population

Keywords

  • Antidepressants
  • Co-morbidity
  • Depression
  • Nortriptyline
  • Open-label
  • Treatment-resistant

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Papakostas, G. I., Petersen, T., Iosifescu, D. V., Roffi, P. A., Alpert, J. E., Rosenbaum, J. F., ... Nierenberg, A. A. (2003). Axis III disorders in treatment-resistant major depressive disorder. Psychiatry Research, 118(2), 183-188. https://doi.org/10.1016/S0165-1781(03)00067-2

Axis III disorders in treatment-resistant major depressive disorder. / Papakostas, George I.; Petersen, Timothy; Iosifescu, Dan V.; Roffi, Pamela A.; Alpert, Jonathan E.; Rosenbaum, Jerrold F.; Fava, Maurizio; Nierenberg, Andrew A.

In: Psychiatry Research, Vol. 118, No. 2, 30.05.2003, p. 183-188.

Research output: Contribution to journalArticle

Papakostas, GI, Petersen, T, Iosifescu, DV, Roffi, PA, Alpert, JE, Rosenbaum, JF, Fava, M & Nierenberg, AA 2003, 'Axis III disorders in treatment-resistant major depressive disorder', Psychiatry Research, vol. 118, no. 2, pp. 183-188. https://doi.org/10.1016/S0165-1781(03)00067-2
Papakostas GI, Petersen T, Iosifescu DV, Roffi PA, Alpert JE, Rosenbaum JF et al. Axis III disorders in treatment-resistant major depressive disorder. Psychiatry Research. 2003 May 30;118(2):183-188. https://doi.org/10.1016/S0165-1781(03)00067-2
Papakostas, George I. ; Petersen, Timothy ; Iosifescu, Dan V. ; Roffi, Pamela A. ; Alpert, Jonathan E. ; Rosenbaum, Jerrold F. ; Fava, Maurizio ; Nierenberg, Andrew A. / Axis III disorders in treatment-resistant major depressive disorder. In: Psychiatry Research. 2003 ; Vol. 118, No. 2. pp. 183-188.
@article{65df27886ebe4f51844cfe580ec2006e,
title = "Axis III disorders in treatment-resistant major depressive disorder",
abstract = "A number of naturalistic studies have found that medical co-morbidity conveys a worse long-term prognosis in the treatment of major depressive disorder (MDD). The purpose of this study was to test whether the presence of co-morbid medical conditions can predict clinical response in patients with treatment-resistant MDD (TRD) treated with open-label nortriptyline (NT). Ninety-two patients with TRD entered a 6-week open trial of NT. The presence of co-morbid medical disorders was assessed during the screen visit. The degree of medical co-morbidity during the screen visit was then quantified with the use of the Cumulative Illness Rating Scale - Geriatric Version (CIRS(G)). We tested whether CIRS(G) scores predicted clinical response or depression severity at endpoint. CIRS scores at baseline did not significantly predict treatment response. The results of this study fail to confirm the relationship between co-morbid medical conditions and poor outcome in the treatment of MDD for patients with TRD. Patients with TRD and co-morbid medical conditions can be expected to respond to antidepressants as well as their counterparts without concurrent axis III co-morbidity. The CIRS(G) scores for this TRD sample were lower than those reported for geriatric depression, or for depressed patients with severe medical illness, common in medical and surgical wards and in most specialty clinics of large academic centers. Thus, the present results cannot be generalized to such populations.",
keywords = "Antidepressants, Co-morbidity, Depression, Nortriptyline, Open-label, Treatment-resistant",
author = "Papakostas, {George I.} and Timothy Petersen and Iosifescu, {Dan V.} and Roffi, {Pamela A.} and Alpert, {Jonathan E.} and Rosenbaum, {Jerrold F.} and Maurizio Fava and Nierenberg, {Andrew A.}",
year = "2003",
month = "5",
day = "30",
doi = "10.1016/S0165-1781(03)00067-2",
language = "English (US)",
volume = "118",
pages = "183--188",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Axis III disorders in treatment-resistant major depressive disorder

AU - Papakostas, George I.

AU - Petersen, Timothy

AU - Iosifescu, Dan V.

AU - Roffi, Pamela A.

AU - Alpert, Jonathan E.

AU - Rosenbaum, Jerrold F.

AU - Fava, Maurizio

AU - Nierenberg, Andrew A.

PY - 2003/5/30

Y1 - 2003/5/30

N2 - A number of naturalistic studies have found that medical co-morbidity conveys a worse long-term prognosis in the treatment of major depressive disorder (MDD). The purpose of this study was to test whether the presence of co-morbid medical conditions can predict clinical response in patients with treatment-resistant MDD (TRD) treated with open-label nortriptyline (NT). Ninety-two patients with TRD entered a 6-week open trial of NT. The presence of co-morbid medical disorders was assessed during the screen visit. The degree of medical co-morbidity during the screen visit was then quantified with the use of the Cumulative Illness Rating Scale - Geriatric Version (CIRS(G)). We tested whether CIRS(G) scores predicted clinical response or depression severity at endpoint. CIRS scores at baseline did not significantly predict treatment response. The results of this study fail to confirm the relationship between co-morbid medical conditions and poor outcome in the treatment of MDD for patients with TRD. Patients with TRD and co-morbid medical conditions can be expected to respond to antidepressants as well as their counterparts without concurrent axis III co-morbidity. The CIRS(G) scores for this TRD sample were lower than those reported for geriatric depression, or for depressed patients with severe medical illness, common in medical and surgical wards and in most specialty clinics of large academic centers. Thus, the present results cannot be generalized to such populations.

AB - A number of naturalistic studies have found that medical co-morbidity conveys a worse long-term prognosis in the treatment of major depressive disorder (MDD). The purpose of this study was to test whether the presence of co-morbid medical conditions can predict clinical response in patients with treatment-resistant MDD (TRD) treated with open-label nortriptyline (NT). Ninety-two patients with TRD entered a 6-week open trial of NT. The presence of co-morbid medical disorders was assessed during the screen visit. The degree of medical co-morbidity during the screen visit was then quantified with the use of the Cumulative Illness Rating Scale - Geriatric Version (CIRS(G)). We tested whether CIRS(G) scores predicted clinical response or depression severity at endpoint. CIRS scores at baseline did not significantly predict treatment response. The results of this study fail to confirm the relationship between co-morbid medical conditions and poor outcome in the treatment of MDD for patients with TRD. Patients with TRD and co-morbid medical conditions can be expected to respond to antidepressants as well as their counterparts without concurrent axis III co-morbidity. The CIRS(G) scores for this TRD sample were lower than those reported for geriatric depression, or for depressed patients with severe medical illness, common in medical and surgical wards and in most specialty clinics of large academic centers. Thus, the present results cannot be generalized to such populations.

KW - Antidepressants

KW - Co-morbidity

KW - Depression

KW - Nortriptyline

KW - Open-label

KW - Treatment-resistant

UR - http://www.scopus.com/inward/record.url?scp=0037870085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037870085&partnerID=8YFLogxK

U2 - 10.1016/S0165-1781(03)00067-2

DO - 10.1016/S0165-1781(03)00067-2

M3 - Article

VL - 118

SP - 183

EP - 188

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 2

ER -